Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0GYNBS
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
XMT-1522
|
|||||
| Synonyms |
TAK 522; TAK-522; TAK522; XMT 1522; XMT-1522; XMT-1522, TAK-522; XMT1522
Click to Show/Hide
|
|||||
| Organization |
Mersana Therapeutics, Inc.; Adimab LLC; Takeda Pharmaceutical Co., Ltd.
|
|||||
| Drug Status |
Phase 1 (Terminated)
|
|||||
| Indication |
In total 3 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
12
|
|||||
| Antibody Name |
XMT-1519
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (HER2)
|
Antigen Info | ||||
| Payload Name |
Auristatin F hydroxypropylamide (AF-HPA)
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Fleximer polymer
|
Linker Info | ||||
| Conjugate Type |
Random Lysines
|
|||||
| TTD ID | ||||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% (Day 49) | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
XMT-1522 (3 mg/kg, every seven days x3) induces efficient tumor cell killing in cell line-derived models of JIMT-1 cells with HER2 expression with high expression.
|
||||
| In Vivo Model | JIMT-1 CDX model | ||||
| In Vitro Model | Breast ductal carcinoma | JIMT-1 cells | CVCL_2077 | ||
References